Published in Curr Opin Rheumatol on September 01, 2010
Interleukin-18 and IL-18 binding protein. Front Immunol (2013) 1.93
Particle disease: biologic mechanisms of periprosthetic osteolysis in total hip arthroplasty. Innate Immun (2012) 1.24
Not all hemophagocytes are created equally: appreciating the heterogeneity of the hemophagocytic syndromes. Curr Opin Rheumatol (2012) 1.10
Familial hemophagocytic lymphohistiocytosis: when rare diseases shed light on immune system functioning. Front Immunol (2014) 1.00
Hemophagocytic macrophages in murine typhoid fever have an anti-inflammatory phenotype. Infect Immun (2012) 0.98
Interferon-γ mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. Arthritis Rheum (2013) 0.97
Systemic arthritis in children: a review of clinical presentation and treatment. Int J Inflam (2011) 0.94
High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome. Mol Med (2015) 0.84
Intravenous immunoglobulin treatment for macrophage activation syndrome complicating chronic granulomatous disease. J Clin Immunol (2011) 0.81
Induction of heme oxygenase-1 by chamomile protects murine macrophages against oxidative stress. Life Sci (2012) 0.81
Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther Adv Musculoskelet Dis (2012) 0.80
Mevalonate kinase deficiency: current perspectives. Appl Clin Genet (2016) 0.80
Follistatin-like protein 1 and the ferritin/erythrocyte sedimentation rate ratio are potential biomarkers for dysregulated gene expression and macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol (2013) 0.79
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. RMD Open (2016) 0.78
Drug Trafficking into Macrophages via the Endocytotic Receptor CD163. Membranes (Basel) (2015) 0.78
Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus. Rheumatol Int (2016) 0.78
Therapeutic Potential of Interferon-γ and Its Antagonists in Autoinflammation: Lessons from Murine Models of Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome. Pharmaceuticals (Basel) (2015) 0.78
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis. Front Pharmacol (2016) 0.77
Specifically targeted delivery of protein to phagocytic macrophages. Int J Nanomedicine (2015) 0.77
Association of IRF5 polymorphisms with susceptibility to hemophagocytic lymphohistiocytosis in children. J Clin Immunol (2011) 0.76
Clinical characteristics and follow-up analysis of adult-onset Still's disease complicated by hemophagocytic lymphohistiocytosis. Clin Rheumatol (2016) 0.75
Increased Von Willebrand factor, decreased ADAMTS13 and thrombocytopenia in melioidosis. PLoS Negl Trop Dis (2017) 0.75
A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment. JCI Insight (2016) 0.75
Coxiella burnetii Infection With Severe Hyperferritinemia in an Asplenic Patient. Open Forum Infect Dis (2015) 0.75
Association of Macrophage Activating Syndrome with Castleman's Syndrome in Systemic Lupus Erythematosus. Iran J Pathol (2016) 0.75
Necrotizing fasciitis in a pediatric patient treated with etanercept and cyclosporine for macrophage activation syndrome. Rheumatol Int (2011) 0.75
New frontiers in the treatment of systemic juvenile idiopathic arthritis. F1000Res (2017) 0.75
Rheumatologic emergencies. Clin Rheumatol (2015) 0.75
HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer (2007) 16.96
Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol (2009) 11.63
Macrophage activation and polarization. Front Biosci (2008) 11.17
Identification of the haemoglobin scavenger receptor. Nature (2001) 7.05
Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet (2000) 5.11
Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell (2003) 4.94
Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science (1999) 4.93
Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med (2005) 4.79
Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet (1998) 3.94
Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol (2005) 3.84
Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol (1997) 3.83
Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program (2009) 2.86
The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum (2007) 2.56
Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature (1996) 2.40
Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child (2001) 2.11
Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum (2007) 2.00
The macrophage scavenger receptor CD163 functions as an innate immune sensor for bacteria. Blood (2008) 1.96
Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis (2006) 1.95
Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol (2007) 1.93
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr (2005) 1.91
Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann Med (2006) 1.65
Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-gamma. J Immunol (1999) 1.61
Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum (2007) 1.54
Primary hemophagocytic syndromes point to a direct link between lymphocyte cytotoxicity and homeostasis. Immunol Rev (2005) 1.52
Reactive haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) (2001) 1.48
Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum (2009) 1.47
Natural killer cell dysfunction: A common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis? Arthritis Rheum (2004) 1.44
Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol (2005) 1.44
Acute hemorrhagic, hepatic, and neurologic manifestations in juvenile rheumatoid arthritis: possible relationship to drugs or infection. J Pediatr (1985) 1.43
Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Pediatr (2003) 1.42
Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther (2004) 1.33
Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. Arthritis Rheum (2008) 1.33
Homeostatic regulation of CD8+ T cells by perforin. Eur J Immunol (1999) 1.29
Mutations in the perforin gene can be linked to macrophage activation syndrome in patients with systemic onset juvenile idiopathic arthritis. Rheumatology (Oxford) (2009) 1.26
Elevated soluble interleukin-2 receptor in childhood hemophagocytic histiocytic syndromes. Blood (1989) 1.19
Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr (1983) 1.19
Is macrophage activation syndrome a new entity? Clin Exp Rheumatol (2002) 1.19
Defective natural killer cell function in patients with hemophagocytic lymphohistiocytosis and in first degree relatives. Pediatr Res (1998) 1.11
Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol (1993) 1.09
Mutations of the hemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum (2008) 1.05
Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation. Rheumatology (Oxford) (2003) 1.00
The soluble interleukin-2 receptor in rheumatic disease. Arthritis Rheum (1990) 1.00
Macrophage activation syndrome: serological markers and treatment with anti-thymocyte globulin. Clin Immunol (2009) 0.95
Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics (2003) 0.93
Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum (2009) 0.92
Macrophage activation syndrome as the presenting manifestation of rheumatic diseases in childhood. J Pediatr (2006) 0.88
Macrophage activation syndrome is hemophagocytic lymphohistiocytosis--need for the right terminology. J Rheumatol (2002) 0.84
The role of heme oxygenase-1 in systemic-onset juvenile idiopathic arthritis. Mod Rheumatol (2009) 0.81
Potential role of interleukin-18 in the immunopathogenesis of AIDS: involvement in fratricidal killing of NK cells. J Virol (2009) 0.81
Retracted CD4+ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy. Sci Transl Med (2013) 2.51
Achieving stability through editing and chaperoning: regulation of MHC class II peptide binding and expression. Immunol Rev (2005) 1.74
Precarious balance: Th17 cells in host defense. Infect Immun (2009) 1.60
Chaperone activity of α B-crystallin is responsible for its incorrect assignment as an autoantigen in multiple sclerosis. J Immunol (2011) 1.56
T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides. Immunity (2009) 1.50
Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus. J Virol (2003) 1.44
Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides. Immunity (2003) 1.43
Role of pediatric and internist rheumatologists in treating children with rheumatic diseases. Pediatrics (2004) 1.39
Breaking old paradigms: Th17 cells in autoimmune arthritis. Clin Immunol (2009) 1.27
HLA-DO acts as a substrate mimic to inhibit HLA-DM by a competitive mechanism. Nat Struct Mol Biol (2012) 1.25
Structural factors contributing to DM susceptibility of MHC class II/peptide complexes. J Immunol (2002) 1.14
Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology (2009) 1.11
Labeling antigen-specific CD4(+) T cells with class II MHC oligomers. J Immunol Methods (2002) 1.11
Oligoarticular and polyarticular JIA: epidemiology and pathogenesis. Nat Rev Rheumatol (2009) 1.11
Selective developmental defects of cord blood antigen-presenting cell subsets. Hum Immunol (2004) 1.09
Human dendritic cell expression of HLA-DO is subset specific and regulated by maturation. J Immunol (2006) 1.06
Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states. Clin Immunol (2009) 1.05
Relationship between kinetic stability and immunogenicity of HLA-DR4/peptide complexes. Eur J Immunol (2002) 1.05
An insertion mutant in DQA1*0501 restores susceptibility to HLA-DM: implications for disease associations. J Immunol (2011) 1.04
DRB1*0401-restricted human T cell clone specific for the major proinsulin73-90 epitope expresses a down-regulatory T helper 2 phenotype. Proc Natl Acad Sci U S A (2006) 1.04
Urine peptidomics for clinical biomarker discovery. Adv Clin Chem (2010) 0.99
Hierarchy of risk of childhood-onset rheumatoid arthritis conferred by HLA-DRB1 alleles encoding the shared epitope. Arthritis Rheum (2012) 0.98
Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis. Proc Natl Acad Sci U S A (2012) 0.97
Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism. J Immunol (2003) 0.97
Plasma profiles in active systemic juvenile idiopathic arthritis: Biomarkers and biological implications. Proteomics (2010) 0.96
Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor. J Immunol (2003) 0.96
Self-antigen recognition by follicular lymphoma B-cell receptors. Blood (2012) 0.95
On the perils of poor editing: regulation of peptide loading by HLA-DQ and H2-A molecules associated with celiac disease and type 1 diabetes. Expert Rev Mol Med (2012) 0.95
Stabilization of soluble, low-affinity HLA-DM/HLA-DR1 complexes by leucine zippers. J Immunol Methods (2002) 0.94
Human cytomegalovirus alters localization of MHC class II and dendrite morphology in mature Langerhans cells. J Immunol (2006) 0.94
Access to pediatric rheumatology care in the United States. Arthritis Rheum (2003) 0.93
Urine Peptidomic and Targeted Plasma Protein Analyses in the Diagnosis and Monitoring of Systemic Juvenile Idiopathic Arthritis. Clin Proteomics (2010) 0.93
Susceptibility to childhood-onset rheumatoid arthritis: investigation of a weighted genetic risk score that integrates cumulative effects of variants at five genetic loci. Arthritis Rheum (2013) 0.93
Medicine on a need-to-know basis. Nat Immunol (2006) 0.92
Candidate early predictors for progression to joint damage in systemic juvenile idiopathic arthritis. J Rheumatol (2006) 0.92
Human cytomegalovirus decreases constitutive transcription of MHC class II genes in mature Langerhans cells by reducing CIITA transcript levels. Mol Immunol (2011) 0.92
Modulation of peripheral B cell tolerance by CD72 in a murine model. Arthritis Rheum (2008) 0.92
DM influences the abundance of major histocompatibility complex class II alleles with low affinity for class II-associated invariant chain peptides via multiple mechanisms. Immunology (2010) 0.91
Formation of two peptide/MHC II isomers is catalyzed differentially by HLA-DM. Biochemistry (2003) 0.90
Latent cytomegalovirus down-regulates major histocompatibility complex class II expression on myeloid progenitors. Blood (2002) 0.90
Cathepsin G: roles in antigen presentation and beyond. Mol Immunol (2009) 0.89
Serum amyloid A overrides Treg anergy via monocyte-dependent and Treg-intrinsic, SOCS3-associated pathways. Blood (2011) 0.88
Bordetella pertussis infection of primary human monocytes alters HLA-DR expression. Infect Immun (2004) 0.87
Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis. Clin Immunol (2010) 0.86
A new era in the treatment of systemic juvenile idiopathic arthritis. N Engl J Med (2012) 0.85
I-Ag7 is subject to post-translational chaperoning by CLIP. Int Immunol (2010) 0.85
Influenza A virus elevates active cathepsin B in primary murine DC. Int Immunol (2007) 0.84
Alternative activation in systemic juvenile idiopathic arthritis monocytes. Clin Immunol (2011) 0.83
Regulatory T cells and their role in rheumatic diseases: a potential target for novel therapeutic development. Pediatr Rheumatol Online J (2008) 0.83
Research priorities in pediatric rheumatology: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) consensus. Pediatr Rheumatol Online J (2008) 0.82
Posttranslational regulation of I-Ed by affinity for CLIP. J Immunol (2007) 0.82
Cytokines elicited by T cell epitopes from a synovial autoantigen: altered peptide ligands can reduce interferon-gamma and interleukin-10 production. Arthritis Rheum (2003) 0.79
Host-derived CD4+ T cells attenuate stem cell-mediated transfer of autoimmune arthritis in lethally irradiated C57BL/6.g7 mice. Arthritis Rheum (2013) 0.79
Correlation analyses of clinical and molecular findings identify candidate biological pathways in systemic juvenile idiopathic arthritis. BMC Med (2012) 0.78
Comparison of transduction efficiency among various lentiviruses containing GFP reporter in bone marrow hematopoietic stem cell transplantation. Exp Hematol (2013) 0.78
Masking of a cathepsin G cleavage site in vivo contributes to the proteolytic resistance of major histocompatibility complex class II molecules. Immunology (2010) 0.77
Clinical research networks: a step towards evidence-based practice in pediatric rheumatology. Nat Clin Pract Rheumatol (2007) 0.77
Retraction of the research article: "CD4⁺ T cell autoimmunity to hypocretin/orexin and cross-reactivity to a 2009 H1N1 influenza A epitope in narcolepsy". Sci Transl Med (2014) 0.75
Viral Vectors Take On HIV Infection. N Engl J Med (2015) 0.75
The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes. J Rheumatol (2017) 0.75